Royalty Pharma PLC $RPRX Stake Raised by Capital International Sarl

Capital International Sarl increased its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 13.5% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 368,562 shares of the biopharmaceutical company’s stock after purchasing an additional 43,879 shares during the quarter. Capital International Sarl’s holdings in Royalty Pharma were worth $13,003,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC boosted its position in Royalty Pharma by 868.1% during the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 790 shares during the period. Financial Consulate Inc. bought a new stake in shares of Royalty Pharma during the third quarter valued at about $35,000. Richardson Financial Services Inc. bought a new stake in shares of Royalty Pharma during the third quarter valued at about $54,000. Farther Finance Advisors LLC lifted its holdings in Royalty Pharma by 44.3% in the third quarter. Farther Finance Advisors LLC now owns 2,060 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 632 shares during the period. Finally, Fifth Third Bancorp increased its stake in Royalty Pharma by 16.9% during the 3rd quarter. Fifth Third Bancorp now owns 2,499 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 362 shares during the period. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on RPRX. Morgan Stanley reaffirmed an “overweight” rating and issued a $61.00 price target on shares of Royalty Pharma in a research note on Thursday, February 12th. TD Cowen reissued a “buy” rating on shares of Royalty Pharma in a report on Friday, February 27th. Citigroup increased their price target on Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Leerink Partners set a $45.00 price objective on Royalty Pharma in a research note on Thursday, December 11th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Royalty Pharma in a research report on Thursday, February 12th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $48.67.

Royalty Pharma Price Performance

Shares of NASDAQ:RPRX opened at $45.84 on Tuesday. The company has a market capitalization of $26.44 billion, a PE ratio of 33.96 and a beta of 0.40. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.40 and a current ratio of 2.40. The stock has a fifty day moving average of $42.67 and a 200-day moving average of $39.31. Royalty Pharma PLC has a one year low of $29.66 and a one year high of $47.86.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.13. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%.The company had revenue of $621.99 million for the quarter, compared to analyst estimates of $839.97 million. As a group, equities analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 20th will be issued a dividend of $0.235 per share. This represents a $0.94 annualized dividend and a yield of 2.1%. The ex-dividend date is Friday, February 20th. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.22. Royalty Pharma’s dividend payout ratio is presently 69.63%.

Insiders Place Their Bets

In related news, EVP Marshall Urist sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $40.26, for a total value of $805,200.00. Following the completion of the transaction, the executive vice president owned 20,000 shares of the company’s stock, valued at approximately $805,200. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Terrance P. Coyne sold 114,954 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $42.84, for a total transaction of $4,924,629.36. Following the sale, the chief financial officer directly owned 23,972 shares in the company, valued at approximately $1,026,960.48. This trade represents a 82.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 737,078 shares of company stock worth $29,862,002 over the last ninety days. 18.90% of the stock is currently owned by company insiders.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.